AbCellera Biologics Inc (NAS:ABCL)
$ 2.995 0.045 (1.53%) Market Cap: 871.33 Mil Enterprise Value: 299.59 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 66/100

Abcellera Biologics Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 11:50PM GMT
Release Date Price: $11.81 (-3.51%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

All right. So welcome, everyone, to the 31st Annual Healthcare Conference Credit Suisse. I'm Tiago Fauth. I'm a biotech analyst at Credit Suisse, joined today by AbCellera. We have Andrew Booth, CFO of the company, for a fireside chat. So an informal conversation about the company for the next 25 minutes or so. Nice to see you in person finally.

Andrew Booth
AbCellera Biologics Inc. - CFO

Finally, yes, a couple of years of working together.

Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

I always like to give you guys a couple of minutes to talk bigger picture about AbCellera business model, big picture things, and I'm going to have several detailed follow-ups after that. But yes, if you could talk -- it's a name that is a little bit unusual from a business model perspective. So I don't know if everyone is super familiar with it. So can you give us the 2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot